Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

Stock Information for Athenex Inc.

Loading

Please wait while we load your information from QuoteMedia.